SAHAJANAND MEDICAL TECHNOLOGIES Q2 FY27 CONCALL: GUIDES MID-TEENS CONSTANT CURRENCY REVENUE GROWTH IN FY27–FY28, TARGETS 150–200 BPS ANNUAL EBITDA MARGIN EXPANSION THROUGH FY29; PLANS ₹70 CR ANNUAL CAPEX, TAVI 2.0 LAUNCH BY Q4 FY27 & WORKING CAPITAL IMPROVEMENT